Treatment of cancer

Collaboration to Improve Bone Health Education Published in Cancer Management and Research

Retrieved on:

Tuesday, May 11, 2021

Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.

Key Points:

Multiple Myeloma and Solid Tumor Patients at Risk for Skeletal-Related Events\xe2\x80\x9d in Cancer Management and Research .\nThe paper highlights findings from the Bone Health Education Needs Assessment (BEACON) Study, most notably, gaps in cancer-related bone health education in cancer patients at risk for skeletal-related events (SREs), indicating an important need for improved communication and education strategies to promote better health outcomes.\n\xe2\x80\x9cThe research conducted as part of the BEACON Study will undoubtedly have an impact on the future of bone health education,\xe2\x80\x9d said Darcy Flora, Ph.D., chief research officer at GRYT Health and lead author on the paper.
from GRYT Health and Benoit Cadieux, Ph.D., Katherine B. Carlson, Ph.D., Kimberly A. Lowe, Ph.D., and Jennifer Schenfeld, MPH, from Amgen, designed the study to help understand patient awareness of cancer-related bone health and to identify opportunities to improve bone health education in cancer patients at risk of SREs.\nThe online BEACON survey included questions about patient demographics, cancer diagnosis and treatments (including use of a BTA), and extent and satisfaction with bone health education received.
Awareness of cancer bone health, protection strategies, and screening tests, however, was low to moderate and patients were least informed of the impact of lifestyle changes (38%) and specific cancer treatments (\xe2\x89\xa435%) on bone health.
Additionally, 62% of patients were not completely satisfied with the bone health education they received.

American Oncology Network Expands Footprint in Northwest with the Addition of Summit Cancer Centers

Retrieved on:

Monday, May 3, 2021

Summit offers comprehensive cancer services from diagnostic imaging, cancer treatments with the most advanced therapies and technologies, clinical trials to onsite oral chemotherapy and lab services.

Key Points:

Summit offers comprehensive cancer services from diagnostic imaging, cancer treatments with the most advanced therapies and technologies, clinical trials to onsite oral chemotherapy and lab services.
Cancer treatments include surgical oncology, chemotherapy, immunotherapy, and other medical oncology therapies.\n\xe2\x80\x9cOur approach is to treat the whole person rather than only focusing on the cancer itself.
As part of this commitment, we offer complementary wellness therapies including acupuncture, cancer massage and nutrition counseling.
Launched in 2018, the rapidly expanding AON network represents 102 physicians and 65 nurse practitioners and physician assistants practicing across 17 states.

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

Retrieved on:

Friday, April 30, 2021

Health sciences, Life sciences, Biotechnology, Drug discovery, Health policy, Medicinal chemistry, Therapy, Chimeric antigen receptor T cell, Treatment of cancer, Biopharmaceutical

b'SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\xe2\x80\x9cGracell\xe2\x80\x9d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:\nOne-on-one and small group meetings: May 13-14, 2021\nFor more information, please contact your Morgan Stanley representative.\nOne-on-one and small group meetings: May 18, 2021\nFor more information, please contact your ICA representative.\nChinese Innovation in IO Panel: 10:10am EDT, May 20, 2021\nFor more information, please contact your Sachs Associates representative.\nGracell Biotechnologies Inc.\xc2\xa0(\xe2\x80\x9cGracell\xe2\x80\x9d) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.

Key Points:

b'SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\xe2\x80\x9cGracell\xe2\x80\x9d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:\nOne-on-one and small group meetings: May 13-14, 2021\nFor more information, please contact your Morgan Stanley representative.\nOne-on-one and small group meetings: May 18, 2021\nFor more information, please contact your ICA representative.\nChinese Innovation in IO Panel: 10:10am EDT, May 20, 2021\nFor more information, please contact your Sachs Associates representative.\nGracell Biotechnologies Inc.\xc2\xa0(\xe2\x80\x9cGracell\xe2\x80\x9d) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies.
Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
For more information on Gracell, please visit www.gracellbio.com\n'

Immunicom Presents Promising Preliminary Data from Multiple Studies in Late-Stage Cancer Patients at ISFA / E-ISFA Conference

Retrieved on:

Friday, April 30, 2021

b"Immunicom, Inc ., a clinical-stage biotechnology company pioneering \xe2\x80\x9csubtractive\xe2\x80\x9d advanced cancer therapies, presented promising preliminary data from trials investigating ImmunopheresisTM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.

Key Points:

b"Immunicom, Inc ., a clinical-stage biotechnology company pioneering \xe2\x80\x9csubtractive\xe2\x80\x9d advanced cancer therapies, presented promising preliminary data from trials investigating ImmunopheresisTM therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
We are developing high-affinity subtractive therapies specifically for these difficult metastatic cancers,\xe2\x80\x9d said Immunicom\xe2\x80\x99s CEO, Amir Jafri.
\xe2\x80\x9cOur mission is to define a new era of cancer treatment that is safe and effective.\xe2\x80\x9d\nDr.
The clinical trials are evaluating the LW-02 column for treating multiple cancers, including triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), metastatic melanoma, and renal cell carcinoma.

Nagourney Cancer Institute Launches Podcast 'Outliving Cancer' to Engage and Inspire

Retrieved on:

Friday, April 30, 2021

Treatment of cancer, Cancer

We have seen so many patients who are alive and well today through the clinical application of our laboratory techniques.

Key Points:

We have seen so many patients who are alive and well today through the clinical application of our laboratory techniques.
Robert Nagourney is an internationally recognized pioneer in cancer research and personalized cancer treatment.
Dr. Nagourney and his team at the Nagourney Cancer Institute have developeda laboratory technique,functional profiling, that measures how cancer cells respond when they are exposed to a wide variety of drugs and drug combinations.
By using this approach, the Nagourney team can determinethe best drugs for each patientbeforethey receive them.\n'

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Retrieved on:

Thursday, April 29, 2021

Health sciences, Chemical compounds, Antineoplastic drugs, Chemistry, Pyrazines, Selinexor, Teratogens, Triazoles, Treatment of cancer, Therapy

Among these media outlets, People.cn stated: "the first patient with rrMM treated with selinexor in the Pilot Zone responded well to the therapy with his condition already stabilized.

Key Points:

Among these media outlets, People.cn stated: "the first patient with rrMM treated with selinexor in the Pilot Zone responded well to the therapy with his condition already stabilized.
Selinexor achieves its antitumor effects by precision targeting the underlying oncogenic pathways, and has a special mechanism of action compared to other approved therapies.
Through the rapid clinical adoption of selinexor in Lecheng, Boao, a much-needed new treatment option has been made available to patients with MM in China.
Although significant progress has been made in treatment, MM is still incurable, mainly due to primary drug resistance and disease recurrence.

Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting

Retrieved on:

Wednesday, April 28, 2021

Clinical medicine, Medicine, Cancer, Cancer treatments, Mitochondria, Oncocyte, Oncology, Adjuvant therapy, Renal cell carcinoma, Treatment of cancer

The presentation will feature data from a study of Oncocyte\xe2\x80\x99s novel predictor of immunotherapy response, DetermaIO\xe2\x84\xa2, demonstrating test performance in renal cell cancer.\n\xe2\x80\x9cWe look forward to presenting these new data which demonstrate DetermaIO, our gene expression-based test which identifies likely immunotherapy responders versus non-responders, is validated in renal cell carcinoma,\xe2\x80\x9d said Doug Ross, M.D., Ph.D., Chief Science Officer of Oncocyte.

Key Points:

The presentation will feature data from a study of Oncocyte\xe2\x80\x99s novel predictor of immunotherapy response, DetermaIO\xe2\x84\xa2, demonstrating test performance in renal cell cancer.\n\xe2\x80\x9cWe look forward to presenting these new data which demonstrate DetermaIO, our gene expression-based test which identifies likely immunotherapy responders versus non-responders, is validated in renal cell carcinoma,\xe2\x80\x9d said Doug Ross, M.D., Ph.D., Chief Science Officer of Oncocyte.
The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.
The Company\xe2\x80\x99s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company.
Oncocyte launched DetermaRx\xe2\x84\xa2, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy.

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Retrieved on:

Monday, April 19, 2021

Clinical medicine, Medicine, Life sciences, Virotherapy, Cancer immunotherapy, Immunotherapy, Treatment of cancer, Biological engineering, Biotechnology, Pharmaceutical industry, Bemcentinib, Bacterial therapy

Naptumomab binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.\n\xe2\x80\x9cThe FDA clearance of the IND for phase II clinical trial of naptumomab in non-small cell lung cancer marks a significant step in the continuing development of naptumomab as well as our collaboration with NeoTX.

Key Points:

Naptumomab binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.\n\xe2\x80\x9cThe FDA clearance of the IND for phase II clinical trial of naptumomab in non-small cell lung cancer marks a significant step in the continuing development of naptumomab as well as our collaboration with NeoTX.
Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase I/II clinical program in patients with advanced solid tumors.
For more information, please visit www.neotx.com.\nNaptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016.
NeoTX is responsible for the global development and commercialization of naptumomab for the treatment of cancer under the license agreement.\n'

Drug Delivery in Cancer 2021: Technologies, Markets & 238 Company Profiles - ResearchAndMarkets.com

Retrieved on:

Friday, April 23, 2021

Pharmaceutical, Health, Oncology, Medicine, Clinical medicine, Medical specialties, Immunology, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer, Drug delivery, Treatment of cancer, Monoclonal antibody, CancerVax

b'The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nDrug delivery remains a challenge in the management of cancer.

Key Points:

b'The "Drug Delivery in Cancer - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nDrug delivery remains a challenge in the management of cancer.
Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer.
Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery.
Important methods of immunotherapy in cancer involve the use of cytokines, monoclonal antibodies, cancer vaccines and immunogene therapy.\nSeveral innovative methods of drug delivery are used in cancer.

CORRECTION: Biotechs Working on Potential Preventive Measures and Cancer Treatments

Retrieved on:

Thursday, April 22, 2021

Clinical medicine, Medicine, Medical specialties, Oncology, Breast cancer, Lumpectomy, Cancer, Treatment of cancer, Ovarian cancer, Melanoma, Breast cancer management, Adjuvant therapy

With evolutionary medical tools, Perimeter Medical hopes to address unmet medical needs and change the process of cancer treatments and prevent the resurfacing of such conditions.

Key Points:

With evolutionary medical tools, Perimeter Medical hopes to address unmet medical needs and change the process of cancer treatments and prevent the resurfacing of such conditions.
It has been reported that breast lumpectomy surgeries have a 25% chance for re-operation because the cancer does not get fully removed the first time.
This tool has the potential to change the future of cancer treatments and reduce the likelihood of a second operation.
The company has been involved in several clinical trials for products that target breast cancer, metastatic melanoma, lung cancer, solid tumors, ovarian cancer, and beyond.